Literature DB >> 21963871

Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

Felix W Santiago1, Theresa Fitzgerald, John J Treanor, David J Topham.   

Abstract

Substantial H5 influenza HA directed immunity is elicited after vaccination of human subjects who had been previously immunized with a drifted H5 HA variant. We sought to investigate the characteristics of H5 HA specific immune responses in more depth by developing an animal model of H5 HA vaccination using drift variants of recombinant H5 HA proteins. HA proteins derived from influenzas A/Vietnam/1203/04 (Clade 1) and A/Indonesia/05/05 (Clade 2.1) were chosen. The sequence of vaccination consisted of two doses of homologous protein, followed by one additional dose of the homologous or heterologous, drifted HA protein. Each dose of HA was combined with CpG as an adjuvant and was injected subcutaneously. All the animals exhibited a serum IgG antibody response that cross-reacted with both HAs in an ELISA. However, those animals that received the drifted variant exhibited higher reactivity to the heterologous HA. Competitive ELISA of serum from drift-variant recipients showed evidence of antibody focusing towards the drifted HA, suggesting modification of the response towards improved cross-reactivity, though development of neutralizing antibodies was limited. Nevertheless, animals were protected against live-virus challenge, and passive transfer of serum was sufficient to confer protection to otherwise naïve mice, indicating that both neutralizing and non-neutralizing antibodies offer some degree of protection. These findings suggest that pre-vaccination against H5 influenza has the potential to prime immunity against emerging drifted H5 strains, and could also lower the dose requirements of vaccination in the event of a pandemic.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963871      PMCID: PMC3202679          DOI: 10.1016/j.vaccine.2011.09.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

Review 1.  Immunogenicity and protective efficacy of influenza vaccination.

Authors:  Claude Hannoun; Francoise Megas; James Piercy
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

2.  Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.

Authors:  D L Lakey; J J Treanor; R F Betts; G E Smith; J Thompson; E Sannella; G Reed; B E Wilkinson; P F Wright
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

3.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

Authors:  Robert B Belshe; Sharon E Frey; Irene Graham; Mark J Mulligan; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry L Keyserling; Paul Spearman; Heather Hill; Mark Wolff
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

4.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

5.  Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

6.  A pandemic warning?

Authors:  J C de Jong; E C Claas; A D Osterhaus; R G Webster; W L Lim
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

7.  Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells.

Authors:  G Hashimoto; P F Wright; D T Karzon
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

8.  Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Authors:  D C Powers; G E Smith; E L Anderson; D J Kennedy; C S Hackett; B E Wilkinson; F Volvovitz; R B Belshe; J J Treanor
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection.

Authors:  M W Verbonitz; F A Ennis; J T Hicks; P Albrecht
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

10.  Disquisitions on Original Antigenic Sin. II. Proof in lower creatures.

Authors:  R G Webster
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

View more
  9 in total

1.  The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

Authors:  Sesquile Ramon; Steven F Baker; Julie M Sahler; Nina Kim; Eric A Feldsott; Charles N Serhan; Luis Martínez-Sobrido; David J Topham; Richard P Phipps
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

2.  Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).

Authors:  Steven F Baker; Aitor Nogales; Felix W Santiago; David J Topham; Luis Martínez-Sobrido
Journal:  Vaccine       Date:  2015-06-01       Impact factor: 3.641

3.  Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

Authors:  Xiangjie Sun; Jessica A Belser; Joanna A Pulit-Penaloza; Hannah M Creager; Zhu Guo; Stacie N Jefferson; Feng Liu; Ian A York; James Stevens; Taronna R Maines; Daniel B Jernigan; Jacqueline M Katz; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-05-26       Impact factor: 3.616

Review 4.  Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses.

Authors:  Lanying Du; Ye Li; Jimin Gao; Yusen Zhou; Shibo Jiang
Journal:  Rev Med Virol       Date:  2012-09-14       Impact factor: 6.989

5.  Lipoxin B4 Enhances Human Memory B Cell Antibody Production via Upregulating Cyclooxygenase-2 Expression.

Authors:  Nina Kim; Katie L Lannan; Thomas H Thatcher; Stephen J Pollock; Collynn F Woeller; Richard P Phipps
Journal:  J Immunol       Date:  2018-10-22       Impact factor: 5.422

6.  Immunopotentiators Improve the Efficacy of Oil-Emulsion-Inactivated Avian Influenza Vaccine in Chickens, Ducks and Geese.

Authors:  Jihu Lu; Peipei Wu; Xuehua Zhang; Lei Feng; Bin Dong; Xuan Chu; Xiufan Liu; Daxin Peng; Yuan Liu; Huailiang Ma; Jibo Hou; Yinghua Tang
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

7.  A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.

Authors:  Lanying Du; Guangyu Zhao; Shihui Sun; Xiujuan Zhang; Xiaojun Zhou; Yan Guo; Ye Li; Yusen Zhou; Shibo Jiang
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

8.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness.

Authors:  Po-Ling Chen; Tsai-Teng Tzeng; Alan Yung-Chih Hu; Lily Hui-Ching Wang; Min-Shi Lee
Journal:  Vaccines (Basel)       Date:  2020-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.